These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29944863)

  • 21. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
    Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
    Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.
    Small AJ; Araujo JL; Leggett CL; Mendelson AH; Agarwalla A; Abrams JA; Lightdale CJ; Wang TC; Iyer PG; Wang KK; Rustgi AK; Ginsberg GG; Forde KA; Gimotty PA; Lewis JD; Falk GW; Bewtra M
    Gastroenterology; 2015 Sep; 149(3):567-76.e3; quiz e13-4. PubMed ID: 25917785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
    Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
    Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
    Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
    J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.
    Vennalaganti P; Kanakadandi V; Goldblum JR; Mathur SC; Patil DT; Offerhaus GJ; Meijer SL; Vieth M; Odze RD; Shreyas S; Parasa S; Gupta N; Repici A; Bansal A; Mohammad T; Sharma P
    Gastroenterology; 2017 Feb; 152(3):564-570.e4. PubMed ID: 27818167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus.
    Nayna L; Emma W; Vani K
    Curr Opin Gastroenterol; 2016 Jul; 32(4):294-301. PubMed ID: 27070914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
    Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
    Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
    Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
    Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia.
    Frei NF; Khoshiwal AM; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Ten Kate FJW; Seldenrijk KA; Meijer SL; Critchley-Thorne RJ; Bergman JJGHM
    Am J Gastroenterol; 2021 Apr; 116(4):675-682. PubMed ID: 33982936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
    O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
    Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
    Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.